Skip to main navigation Skip to search Skip to main content

C-19: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-C

Project: Research

Project Details

StatusActive
Effective start/end date07/13/20 → 06/30/26

Funding

  • Regeneron Pharmaceuticals Incorporated: $323,482.16